key: cord-0844397-r3a6tx0t
authors: Zhou, Ziliang; Huang, Chunliu; Zhou, Zhechong; Huang, Zhaoxia; Su, Lili; Kang, Sisi; Chen, Xiaoxue; Chen, Qiuyue; He, Suhua; Rong, Xia; Xiao, Fei; Chen, Jun; Chen, Shoudeng
title: Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor for human CD14+ monocytes
date: 2021-02-12
journal: iScience
DOI: 10.1016/j.isci.2021.102187
sha: 89756a050931d9a1ed98412260037eb908e6d7ce
doc_id: 844397
cord_uid: r3a6tx0t

Dysregulated immune cell responses have been linked to the severity of coronavirus disease 2019 (COVID-19), but the specific viral factors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were currently unknown. Herein, we reveal that the Ig-like fold ectodomain of the viral protein SARS-CoV-2 ORF7a interacts with high efficiency to CD14+ monocytes in human peripheral blood, compared to pathogenic protein SARS-CoV ORF7a. The crystal structure of SARS-CoV-2 ORF7a at 2.2 Å resolution reveals three remarkable changes on the amphipathic side of the four-stranded β-sheet, implying a potential functional interface of the viral protein. Importantly, SARS-CoV-2 ORF7a coincubation with CD14+ monocytes ex vivo triggered a decrease in HLA-DR/DP/DQ expression levels and upregulated significant production of proinflammatory cytokines, including IL-6, IL-1β, IL-8, and TNF-α. Our work demonstrates that SARS-CoV-2 ORF7a is an immunomodulating factor for immune cell binding and triggers dramatic inflammatory responses, providing promising therapeutic drug targets for pandemic COVID-19.

disease 2019 (COVID-19), but the specific viral factors of severe acute respiratory 29 syndrome coronavirus 2 (SARS-CoV-2) were currently unknown. Herein, we reveal 30 that the Ig-like fold ectodomain of the viral protein SARS-CoV-2 ORF7a interacts 31 with high efficiency to CD14 + monocytes in human peripheral blood, compared to 32 pathogenic protein SARS-CoV ORF7a. The crystal structure of SARS-CoV-2 ORF7a 33 at 2.2 Å resolution reveals three remarkable changes on the amphipathic side of the 34 four-stranded β-sheet, implying a potential functional interface of the viral protein. monocytes in the immunopathology of COVID-19 patients. A recent study found that 58 the percentage of CD14 + CD16 + inflammatory monocytes in the peripheral blood was 59 higher in the 33 hospitalized patients diagnosed with COVID-19, especially in 60 intensive care unit (ICU) patients (Zhou et al., 2020) . Additionally, a significant 61 increase in IL-6 production of inflammatory CD14 + CD16 + monocytes was noted in 62 mild and severe COVID-19 patients, suggesting that monocytes are key contributors 63 to cytokine storms in COVID-19 (Zhou et al., 2020 CoV-2 ORF7a, especially related to its potential ability to bind to immune cells. 88

Herein, we discovered high binding efficiency of SARS-CoV-2 ORF7a to human 89 monocytes via viral protein-based flow cytometry and cell surface marker analysis 90 but did not find similar results for SARS-CoV ORF7a. We then solved the crystal 91 structure of SARS-CoV-2 ORF7a at 2.2 Å resolution. Structure-based 92 superimposition indicates that the residue variations on the potential intramolecular 93 interfaces are probably critical for its binding capability. Furthermore, we sought to 94 identify the biological significance of SARS-CoV-2 ORF7a-leukocyte interactions 95 and subsequent immune responses, which may provide potential therapeutic targets 96 for pandemic COVID-19. (Transparent Methods). The structure was determined by molecular replacement 130 using the SARS-CoV ORF7a structure (PDB ID: 1XAK) as the search model (Nelson 131 et al., 2005) . The final structure, with a visible electron density spanning residues 132 14-82, was refined to R-factor and R-free values of 0.201 and 0.246, respectively. 133

All the statistics for the data collection, phasing, and refinement are presented in 134 Table S1 . 135

The overall structure of the SARS-CoV-2 ORF7a consists of seven β-strands divided 136 into two tightly packed β-sheets (Figures 2A and S1B) . Strands A, G, F, and C form 137 the larger 4-stranded β-sheet, while strands B, E, and D compose the smaller 3-138 stranded β-sheet. Two disulfide bonds (formed by residues Cys23-Cys58 and 139

Cys35-Cys67) stabilize the β-sheet structure ''sandwich'' by connecting strand A to 140 the EF loop and the BC loop to the FG loop (Figures 2A and S1B) . The SARS-CoV- To identify the proteins with structural similarity to the SARS-CoV-2 ORF7a, we next 166 performed network service DALI searching of the PDB database (Holm, 2020). 6.1, RMSD of 2.5 Å for 65 aligned residues, with 8% sequence identity) ( Table S2) . To further validate the similarity of these proteins, we compared their topological and CoV-2 ORF7a and the ICAM3 D1 domain is different (Figure S2E) CoV-2 ORF7a counterparts (Figures S2D and S2F) . Also, we compared SARS-198

CoV-2 ORF7a to ICAM1, ICAM2, and IL-1R, respectively (Figure S3) (Hanel and Willbold, 2007). Therefore, we aligned the key residues Glu41 or Glu37 212 between these two structures ( Figure 4A ). As shown in Figures S1C, S1D, and 4A , 213 the varied residues were located on the same surface facing toward the LFA-1 214 interaction sites. LFA-1 binding is mediated by Mg 2+ via the recognition of Glu37 of 215 ICAM3 in the ICAM3-LFA-1 complex (Figures 4A and 4B) . The varied residues 216

Lys72 and Gln62 of SARS-CoV-2 ORF7a show significant clashes to the 217 counterparts Leu204 and Met140 of LFA-1 at the interaction surface, respectively 218 ( Figures 4C and 4D) . These results suggest that the interaction pattern of SARS-219

CoV-2 ORF7a to leukocytes may not be similar to the ICAM3-LFA-1 complex. 220

To test the hypothesis suggesting structural dissimilarities in LFA-1 interactions, we little interaction between LFA-1 and SARS-CoV-2 ORF7a, indicating that the 228 interaction of SARS-CoV-2 ORF7a with immune cells is independent of LFA-1. 229

To investigate the biological significance of the SARS-CoV-2 ORF7a protein binding 231 to immune cells, the ORF7a protein ectodomain was incubated with human PBMCs 232 from healthy donors for 24 hours, and the expression levels of the surface molecules 233 on the PBMCs were then analyzed by flow cytometry. As shown in Figure 5A For the first time, to our knowledge, we demonstrate that SARS-CoV-2 ORF7a 278 ectodomain binds to CD14 + monocytes in human peripheral blood with high 279 efficiency (Figures 1B and 1F) , whereas SARS-CoV ORF7a ectodomain shows a 280 significantly lower binding ability to monocytes (Figure 1F between SARS-CoV-2 ORF7a and monocytes indicate that SARS-CoV-2 ORF7a is 289 probably a key viral factor that contributes to the recruitment of monocytes to 290 infected lungs during COVID-19. 291

We further solved the crystal structure of SARS-CoV-2 accessory protein ORF7a 292 ectodomain, a COVID-19 factor, to explore the mechanism of the different binding 293 capabilities of SARS-CoV-2 ORF7a and SARS-CoV ORF7a to human monocytes. 294

Considering the structure alignment results, we discovered that SARS-CoV-2 ORF7a 295 is structurally similar to SARS-CoV ORF7a (PDB ID: 1XAK). All of these varied 296 residues are mainly distributed at the amphipathic side of the larger 4-stranded β-297

sheet, which may be the potential functional interface. This structure is very likely to 298 be basis of the molecular mechanism underlying the different pathological processes 299 of SARS strains. However, the structural alignment results between SARS-CoV-2 300

ORF7a with ICAM proteins, the similar protein family to SARS-CoV ORF7a, suggest 301 that the interaction pattern of SARS-CoV-2 ORF7a to leukocytes may not be similar 302 to the ICAM-LFA-1 complex. Indeed, four kinds of in vitro protein-protein interaction 303 assays support this observation. All of the assays demonstrate the interactions of the 304 SARS-CoV-2 ORF7a to leukocytes are independent of LFA-1. 305

To further investigate the consequence of the viral protein bound to monocytes, we 306 next explored the immune response of human monocytes ex vivo. SARS-CoV-2 307

ORF7a binding to CD14 + monocytes led to a significant decrease in the HLA-308 DR/DP/DQ molecules on CD14 + monocytes, which suggests that ORF7a may 309 suppress the antigen-presenting ability of these monocytes (Figure 5A ). It will be 310 interesting to functionally characterize how SARS-CoV-2 ORF7a modulates the 

This study demonstrated that SARS-CoV-2 ORF7a was essential for the binding of 332 SARS-CoV-2 to human CD14 + monocytes. Although we indicated that SARS-CoV-2 333

ORF7a triggers the antigen-presenting suppression of CD14 + monocytes and is 334 involved in cytokine storm propagation of COVID-19 patients, we could not specify 335 the direct binding molecule. 336 

Single-cell landscape of bronchoalveolar immune cells in 433 patients with COVID-19

COVID-19: consider cytokine 436 storm syndromes and immunosuppression

Structure and intracellular targeting of the SARS-coronavirus ORF7a accessory 439 protein

Dysregulation of immune response in patients with COVID-442 19 in Wuhan, China

Differential Redistribution of Activated Monocyte

Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19. medRxiv

Elevated calprotectin 461 and abnormal myeloid cell subsets discriminate severe from mild COVID-19

An atomic resolution view of ICAM recognition in a complex 465 between the binding domains of ICAM-3 and integrin alpha(L)beta(2)

Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis 469 of SARS-CoV-2-Related Viruses

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Weekly update on COVID-19 -23

Structural 482 basis for the recognition of SARS-CoV-2 by full-length human ACE2

Pathogenic T-cells and inflammatory monocytes incite inflammatory 486 storms in severe COVID-19 patients

Ig-like SARS-CoV-2 ORF7a efficiently interacts with CD14 + monocytes from PBMCs